{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:32:11Z","timestamp":1773847931536,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10585-024-10324-z","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:41:58Z","timestamp":1734356518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Multi-institutional study using sbrt to treat mediastinal and hilar lymphadenopathy"],"prefix":"10.1007","volume":"42","author":[{"given":"D.","family":"Caivano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bonome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Ricciardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Zuccoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. C.","family":"Sigillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Serio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Menichelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Valeriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Osti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"5","key":"10324_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.clon.2022.02.010","volume":"34","author":"P Diez","year":"2022","unstructured":"Diez P, Hanna GG, Aitken KL et al (2022) UK 2022 Consensus on normal tissue dose-volume constraints for Oligometastatic, primary lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy. Clin Oncol (R Coll Radiol) 34(5):288\u2013300. https:\/\/doi.org\/10.1016\/j.clon.2022.02.010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10324_CR2","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-15-0822","volume":"21","author":"DA Palma","year":"2015","unstructured":"Palma DA, Louie AV, Rodrigues GB (2015) New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res 21:5198\u20135204","journal-title":"Clin Cancer Res"},{"key":"10324_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases J Clinoncol 13:8\u201310. https:\/\/doi.org\/10.1200\/JCO.1995.13.1.8","journal-title":"Oligometastases J Clinoncol"},{"key":"10324_CR4","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4:e173501","journal-title":"JAMA Oncol"},{"key":"10324_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1200\/JCO.19.00201","volume":"37","author":"DR Gomez","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J et al (2019) Local consolidative therapy Vs. maintenance Therapy or Observation for patients with Oligometastatic Non-small-cell Lung Cancer: long-term results of a multi-institutional, phase II, Randomized Study. J Clin Oncol 37:1558\u20131565","journal-title":"J Clin Oncol"},{"key":"10324_CR6","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051\u20132058","journal-title":"Lancet"},{"issue":"25","key":"10324_CR7","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"issue":"1","key":"10324_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","volume":"7","author":"EJ Lehrer","year":"2021","unstructured":"Lehrer EJ, Singh R, Wang M et al (2021) Safety and Survival Rates Associated with Ablative Stereotactic Radiotherapy for patients with Oligometastatic Cancer: a systematic review and Meta-analysis. JAMA Oncol 7(1):92\u2013106. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6146","journal-title":"JAMA Oncol"},{"key":"10324_CR9","doi-asserted-by":"publisher","unstructured":"Caivano D, Bonome P, Pezzulla D et al (2023) Stereotactic body radiation therapy for the treatment of lymph node metastases: a retrospective mono-institutional study in a large cohort of patients. Front Oncol. 2023;13:1163213. https:\/\/doi.org\/10.3389\/fonc.2023.1163213. Ecollection 2023","DOI":"10.3389\/fonc.2023.1163213"},{"issue":"7","key":"10324_CR10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","volume":"32","author":"G Macchia","year":"2022","unstructured":"Macchia G, Jereczek-Fossa BA, Lazzari R, Cerrotta A, Deodato F, Ippolito E, Aristei C, Gambacorta MA, Scambia G, Valentini V, Ferrandina G (2022) Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD). Int J Gynecol Cancer 32(7):939\u2013943. https:\/\/doi.org\/10.1136\/ijgc-2021-002709","journal-title":"Int J Gynecol Cancer"},{"issue":"11","key":"10324_CR11","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.21037\/jtd-2019-cptn-01","volume":"12","author":"D Owen","year":"2020","unstructured":"Owen D, Sio TT (2020) Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors. J Thorac Dis 12(11):7024\u20137031. https:\/\/doi.org\/10.21037\/jtd-2019-cptn-01","journal-title":"J Thorac Dis"},{"issue":"2","key":"10324_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.radonc.2018.07.001","volume":"129","author":"JH Chang","year":"2018","unstructured":"Chang JH, Poon I, Erler D, Zhang L, Cheung P (2018) The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors. Radiother Oncol 129(2):277\u2013283. https:\/\/doi.org\/10.1016\/j.radonc.2018.07.001","journal-title":"Radiother Oncol"},{"issue":"7","key":"10324_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.jtho.2021.03.019","volume":"16","author":"K Lindberg","year":"2021","unstructured":"Lindberg K, Grozman V, Karlsson K et al (2021) The HILUS-Trial\u2014a prospective nordic Multicenter phase 2 study of Ultracentral Lung tumors treated with stereotactic body Radiotherapy. J Thorac Oncol 16(7):1200\u20131210. https:\/\/doi.org\/10.1016\/j.jtho.2021.03.019","journal-title":"J Thorac Oncol"},{"key":"10324_CR14","doi-asserted-by":"publisher","unstructured":"Giuliani ME, Filion E, Faria S, Kundapur V et al (2024) Stereotactic Radiation for Ultra-central Non-small Cell Lung Cancer: a Safety and Efficacy Trial (SUNSET). Int J Radiat Oncol Biol Phys S0360-3016(24)00480-2. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.03.050","DOI":"10.1016\/j.ijrobp.2024.03.050"},{"issue":"15","key":"10324_CR15","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.18.00622","volume":"37","author":"A Bezjak","year":"2019","unstructured":"Bezjak A, Paulus R, Gaspar LE et al (2019) Safety and Efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell Lung Cancer: NRG Oncology\/RTOG 0813 Trial. J Clin Oncol 37(15):1316\u20131325. https:\/\/doi.org\/10.1200\/JCO.18.00622","journal-title":"J Clin Oncol"},{"issue":"11","key":"10324_CR16","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.3390\/cancers14112680","volume":"14","author":"S Cozzi","year":"2022","unstructured":"Cozzi S, Al\u00ec E, Bardoscia L et al (2022) Stereotactic body Radiation Therapy (SBRT) for Oligorecurrent\/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: a systematic review cancers. (Basel) 14(11):2680. https:\/\/doi.org\/10.3390\/cancers14112680","journal-title":"(Basel)"},{"issue":"4","key":"10324_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","volume":"18","author":"RD Timmerman","year":"2008","unstructured":"Timmerman RD (2008) An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol 18(4):215\u2013222. https:\/\/doi.org\/10.1016\/j.semradonc.2008.04.001","journal-title":"Semin Radiat Oncol"},{"key":"10324_CR18","doi-asserted-by":"publisher","first-page":"110335","DOI":"10.1016\/j.radonc.2024.110335","volume":"197","author":"D Franceschini","year":"2024","unstructured":"Franceschini D, Teriaca MA, Mancosu P et al (2024) Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases. Radiother Oncol 197:110335. https:\/\/doi.org\/10.1016\/j.radonc.2024.110335","journal-title":"Radiother Oncol"},{"key":"10324_CR19","doi-asserted-by":"publisher","first-page":"15690","DOI":"10.18632\/oncotarget.3704","volume":"6","author":"MB Meng","year":"2022","unstructured":"Meng MB, Wang HH, Zaorsky NG et al (2022) Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer. Oncotarget 6:15690\u201315703","journal-title":"Oncotarget"},{"key":"10324_CR20","doi-asserted-by":"publisher","first-page":"53321","DOI":"10.18632\/oncotarget.10826","volume":"7","author":"D Franceschini","year":"2016","unstructured":"Franceschini D, De Rose F, Fogliata A et al (2016) Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease. Oncotarget 7:53321\u201353329","journal-title":"Oncotarget"},{"key":"10324_CR21","doi-asserted-by":"publisher","first-page":"18135","DOI":"10.18632\/oncotarget.7636","volume":"7","author":"HH Wang","year":"2016","unstructured":"Wang HH, Zairsky NG, Meng MB et al (2016) Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes. Oncotarget 7:18135\u201318145","journal-title":"Oncotarget"},{"key":"10324_CR22","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11604-018-0776-6","volume":"36","author":"Y Manabe","year":"2018","unstructured":"Manabe Y, Shibamoto Y, Baba F et al (2018) Definitive radiotherapy for hilar and\/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results. Jpn J Radiol 36:719\u2013725","journal-title":"Jpn J Radiol"},{"key":"10324_CR23","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1111\/1759-7714.13501","volume":"11","author":"RO Kowalchuk","year":"2020","unstructured":"Kowalchuk RO, Waters MR, Richardson M et al (2020) Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: analysis of outcomes in patients receiving one or multiple courses of treatment. Thorac Cancer 11:2005\u20132013","journal-title":"Thorac Cancer"},{"issue":"2","key":"10324_CR24","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijrobp.2022.05.021","volume":"114","author":"M Buckstein","year":"2022","unstructured":"Buckstein M, Kim E, \u00d6zbek U et al (2022) Combination Transarterial Chemoembolization and Stereotactic Body Radiation Therapy for Unresectable single large Hepatocellular Carcinoma: results from a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 114(2):221\u2013230. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10324_CR25","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1136\/ijgc-2021-003237","volume":"32","author":"G Macchia","year":"2022","unstructured":"Macchia G, Nardangeli A, Laliscia C et al (2022) Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2\/RAD study): a collaboration of MITO, AIRO GYN, and mango groups. Int J Gynecol Cancer 32(6):732\u2013739","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10324_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ijrobp.2023.04.025","volume":"117","author":"G Macchia","year":"2023","unstructured":"Macchia G, Pezzulla D, Campitelli M et al (2023) Efficacy and safety of stereotactic body Radiation Therapy in Oligometastatic Uterine Cancer (MITO-RT2\/RAD): a large, real-world study in Collaboration with Italian Association of Radiation Oncology, Multicenter Italian trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups. Int J Radiat Oncol Biol Phys 117(2):321\u2013332","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10324_CR27","doi-asserted-by":"publisher","first-page":"20181026","DOI":"10.1259\/bjr.20181026","volume":"92","author":"D Franceschini","year":"2019","unstructured":"Franceschini D, Bianciardi F, Mazzola R et al (2019) Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy? BR. J Radiol 92:20181026","journal-title":"J Radiol"},{"key":"10324_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2017.10.014","volume":"115","author":"ZD Horne","year":"2018","unstructured":"Horne ZD, Richman AH, Dohopolski MJ et al (2018) Stereotactic body radiation therapy forisolated hilar and mediastinal non-small cell lung cancers. Lung Cancer 115:1\u20134","journal-title":"Lung Cancer"},{"key":"10324_CR29","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1080\/0284186X.2018.1486040","volume":"57","author":"BA Jereczek-Fossa","year":"2018","unstructured":"Jereczek-Fossa BA, Muto M, Durante S et al (2018) Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a \u2018no-fly zone\u2019? Acta Oncol 57:1532\u20131539","journal-title":"Acta Oncol"},{"key":"10324_CR30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13014-017-0820-1","volume":"12","author":"R Yeung","year":"2017","unstructured":"Yeung R, Hamm J, Liu M, Shellenberg D (2017) Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 12:105","journal-title":"Radiat Oncol"},{"key":"10324_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ygyno.2024.01.023","volume":"184","author":"G Macchia","year":"2024","unstructured":"Macchia G, Cilla S, Pezzulla D et al (2024) Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer. Gynecol Oncol 184:16\u201323. https:\/\/doi.org\/10.1016\/j.ygyno.2024.01.023Epub 2024 Jan 24","journal-title":"Gynecol Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-024-10324-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-024-10324-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T08:02:14Z","timestamp":1738742534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-024-10324-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10324"],"URL":"https:\/\/doi.org\/10.1007\/s10585-024-10324-z","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"6 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"4"}}